Loading
A phase 1/2 trial of ENV-501 in melanoma and non-small-cell lung cancer, run by Hummingbird Bioscience, now recruiting.
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors is a phase 1/2 interventional study registered as NCT06956690 by Hummingbird Bioscience, with 180 participants planned, started 2025-12-17 and due to reach its primary completion in 2027-07. Interventions recorded: ENV-501. Conditions listed: Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.